| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interleukin-10 | 4 | 2026 | 74 | 1.810 |
Why?
|
| Prostatic Neoplasms | 3 | 2026 | 304 | 1.450 |
Why?
|
| Interleukin-18 | 2 | 2026 | 18 | 1.410 |
Why?
|
| Ovarian Neoplasms | 8 | 2025 | 607 | 1.290 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 415 | 1.130 |
Why?
|
| Polycomb Repressive Complex 1 | 6 | 2018 | 34 | 1.110 |
Why?
|
| Inflammation | 3 | 2026 | 669 | 1.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2026 | 9 | 0.950 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2026 | 9 | 0.950 |
Why?
|
| Transcription Factor RelA | 1 | 2026 | 22 | 0.950 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 405 | 0.850 |
Why?
|
| Monkeypox virus | 1 | 2024 | 1 | 0.830 |
Why?
|
| Carcinosarcoma | 2 | 2025 | 31 | 0.680 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 171 | 0.660 |
Why?
|
| Uterine Neoplasms | 2 | 2025 | 80 | 0.650 |
Why?
|
| MicroRNAs | 3 | 2022 | 303 | 0.630 |
Why?
|
| Cystathionine beta-Synthase | 4 | 2023 | 31 | 0.630 |
Why?
|
| DNA Damage | 2 | 2022 | 152 | 0.610 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 123 | 0.580 |
Why?
|
| Oxazepines | 3 | 2013 | 4 | 0.570 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 285 | 0.520 |
Why?
|
| Promoter Regions, Genetic | 3 | 2016 | 344 | 0.510 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 1360 | 0.500 |
Why?
|
| Apoptosis | 6 | 2018 | 781 | 0.490 |
Why?
|
| Metal Nanoparticles | 3 | 2025 | 137 | 0.480 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 33 | 0.470 |
Why?
|
| Humans | 34 | 2026 | 29078 | 0.460 |
Why?
|
| Isoxazoles | 2 | 2014 | 8 | 0.450 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 686 | 0.450 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2014 | 24 | 0.440 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 79 | 0.430 |
Why?
|
| Interleukin-12 | 1 | 2014 | 19 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2015 | 247 | 0.420 |
Why?
|
| Cell Proliferation | 9 | 2020 | 827 | 0.400 |
Why?
|
| Drug Design | 1 | 2013 | 63 | 0.390 |
Why?
|
| Amino Acids | 1 | 2013 | 85 | 0.390 |
Why?
|
| Tobacco Use | 1 | 2014 | 103 | 0.390 |
Why?
|
| Animals | 18 | 2025 | 10756 | 0.370 |
Why?
|
| Mice, Nude | 7 | 2019 | 333 | 0.340 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 43 | 0.340 |
Why?
|
| Female | 21 | 2025 | 15740 | 0.340 |
Why?
|
| Trans-Activators | 1 | 2011 | 118 | 0.330 |
Why?
|
| Survival Rate | 3 | 2016 | 433 | 0.320 |
Why?
|
| Aged | 7 | 2026 | 5627 | 0.310 |
Why?
|
| Prognosis | 2 | 2026 | 815 | 0.300 |
Why?
|
| RNA, Messenger | 2 | 2025 | 668 | 0.290 |
Why?
|
| Cell Movement | 5 | 2019 | 377 | 0.290 |
Why?
|
| Follow-Up Studies | 2 | 2026 | 1033 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 276 | 0.290 |
Why?
|
| Mice | 10 | 2025 | 4845 | 0.280 |
Why?
|
| Cation Transport Proteins | 2 | 2020 | 60 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 472 | 0.250 |
Why?
|
| Middle Aged | 6 | 2026 | 7458 | 0.250 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 140 | 0.240 |
Why?
|
| Gene Transfer Techniques | 1 | 2025 | 74 | 0.230 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 334 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 314 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 121 | 0.220 |
Why?
|
| Case-Control Studies | 2 | 2026 | 740 | 0.220 |
Why?
|
| Mitochondria | 2 | 2020 | 418 | 0.220 |
Why?
|
| Gold | 3 | 2025 | 137 | 0.210 |
Why?
|
| Signal Transduction | 6 | 2020 | 1482 | 0.210 |
Why?
|
| Hydrogen Sulfide | 3 | 2023 | 33 | 0.210 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 484 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 1 | 2024 | 93 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 236 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 348 | 0.190 |
Why?
|
| Astrocytes | 1 | 2023 | 80 | 0.190 |
Why?
|
| Rad51 Recombinase | 1 | 2022 | 10 | 0.190 |
Why?
|
| Phosphorylation | 3 | 2019 | 585 | 0.190 |
Why?
|
| Histones | 2 | 2019 | 96 | 0.180 |
Why?
|
| Risk Factors | 2 | 2019 | 2138 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 433 | 0.180 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2013 | 26 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2013 | 21 | 0.170 |
Why?
|
| Tuberculosis | 2 | 2013 | 25 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2022 | 163 | 0.170 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2020 | 23 | 0.170 |
Why?
|
| Male | 6 | 2026 | 14049 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2013 | 33 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 2 | 2020 | 62 | 0.170 |
Why?
|
| Glycolysis | 2 | 2020 | 96 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mitochondrial Dynamics | 1 | 2020 | 18 | 0.160 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Histone Deacetylase 2 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 59 | 0.160 |
Why?
|
| Cytokines | 1 | 2022 | 456 | 0.150 |
Why?
|
| Apelin Receptors | 1 | 2019 | 11 | 0.150 |
Why?
|
| Adult | 5 | 2025 | 8080 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 165 | 0.140 |
Why?
|
| Brain | 1 | 2023 | 770 | 0.140 |
Why?
|
| Pyrazines | 1 | 2017 | 26 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2017 | 32 | 0.130 |
Why?
|
| MCF-7 Cells | 2 | 2014 | 34 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 189 | 0.120 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 15 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 20 | 0.120 |
Why?
|
| India | 2 | 2014 | 150 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2016 | 428 | 0.120 |
Why?
|
| Chaperonin 60 | 2 | 2013 | 2 | 0.120 |
Why?
|
| Aging | 1 | 2023 | 1029 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2020 | 680 | 0.120 |
Why?
|
| Homeostasis | 1 | 2016 | 119 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 270 | 0.110 |
Why?
|
| Rats | 4 | 2011 | 1594 | 0.110 |
Why?
|
| Gene Frequency | 1 | 2015 | 188 | 0.110 |
Why?
|
| Luciferases | 2 | 2014 | 54 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 203 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2014 | 87 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 153 | 0.110 |
Why?
|
| Alleles | 1 | 2015 | 357 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2016 | 77 | 0.110 |
Why?
|
| Transfection | 1 | 2015 | 319 | 0.110 |
Why?
|
| Age Distribution | 1 | 2014 | 75 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2014 | 78 | 0.110 |
Why?
|
| Cell Line | 2 | 2019 | 701 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 461 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2070 | 0.100 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 6 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 261 | 0.100 |
Why?
|
| Binding Sites | 2 | 2011 | 355 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 88 | 0.100 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2013 | 2 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2013 | 6 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 523 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2016 | 876 | 0.090 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2011 | 16 | 0.090 |
Why?
|
| Pterocarpans | 1 | 2011 | 1 | 0.090 |
Why?
|
| Bacterial Proteins | 2 | 2013 | 499 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2011 | 14 | 0.080 |
Why?
|
| Tyrosine | 1 | 2011 | 92 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2011 | 39 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 787 | 0.080 |
Why?
|
| Estrogens | 1 | 2011 | 56 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 41 | 0.080 |
Why?
|
| Thermodynamics | 1 | 2011 | 93 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2025 | 201 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2011 | 73 | 0.080 |
Why?
|
| Cell Survival | 3 | 2018 | 420 | 0.080 |
Why?
|
| Polypropylenes | 1 | 2010 | 6 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 556 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2011 | 78 | 0.080 |
Why?
|
| Dendrimers | 1 | 2010 | 15 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 18 | 0.080 |
Why?
|
| Folic Acid | 1 | 2010 | 34 | 0.080 |
Why?
|
| Pyrones | 1 | 2009 | 6 | 0.080 |
Why?
|
| Nanostructures | 1 | 2010 | 64 | 0.070 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2009 | 11 | 0.070 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2009 | 9 | 0.070 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2008 | 1 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2010 | 119 | 0.070 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 103 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 68 | 0.070 |
Why?
|
| Liver | 1 | 2011 | 493 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 86 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 524 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 645 | 0.060 |
Why?
|
| Insulin | 2 | 2022 | 325 | 0.060 |
Why?
|
| Cisplatin | 2 | 2017 | 186 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2020 | 1022 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 35 | 0.060 |
Why?
|
| Endosomes | 1 | 2025 | 53 | 0.060 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2025 | 40 | 0.060 |
Why?
|
| Carboplatin | 1 | 2025 | 121 | 0.060 |
Why?
|
| Endocytosis | 1 | 2025 | 97 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2025 | 80 | 0.060 |
Why?
|
| Protein Binding | 2 | 2017 | 667 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 226 | 0.050 |
Why?
|
| Cystathionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Recombinational DNA Repair | 1 | 2022 | 7 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2022 | 31 | 0.050 |
Why?
|
| Opium | 1 | 2022 | 2 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 137 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 82 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 83 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 83 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 251 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 198 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2020 | 80 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 525 | 0.040 |
Why?
|
| Sputum | 2 | 2010 | 8 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 90 | 0.040 |
Why?
|
| Zebrafish | 1 | 2020 | 96 | 0.040 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 7 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 882 | 0.040 |
Why?
|
| Pyrans | 1 | 2019 | 8 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2011 | 554 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2019 | 139 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 1522 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2011 | 453 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 97 | 0.040 |
Why?
|
| Caspases | 1 | 2018 | 43 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 95 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 108 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 117 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 158 | 0.030 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 465 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 65 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 481 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2017 | 17 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 480 | 0.030 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2016 | 6 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Lysine Acetyltransferase 5 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 243 | 0.030 |
Why?
|
| Neuropilins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 2015 | 13 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 56 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 76 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 141 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 688 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 179 | 0.030 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2014 | 5 | 0.030 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Calcineurin | 1 | 2014 | 7 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 14 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 17 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 267 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 34 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 31 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 86 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2014 | 96 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2014 | 72 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 202 | 0.020 |
Why?
|
| Mutation | 1 | 2017 | 873 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 116 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 30 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 60 | 0.020 |
Why?
|
| Sesquiterpenes | 1 | 2011 | 22 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 90 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 44 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 45 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 103 | 0.020 |
Why?
|
| Uterus | 1 | 2011 | 31 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 27 | 0.020 |
Why?
|
| Skull | 1 | 2011 | 41 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2011 | 30 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2011 | 41 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 267 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 23 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2010 | 9 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2010 | 28 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 94 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2010 | 26 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 73 | 0.020 |
Why?
|
| Hemolysis | 1 | 2010 | 51 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 72 | 0.020 |
Why?
|
| Lithium Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cyclization | 1 | 2009 | 2 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 2009 | 3 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2010 | 32 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 134 | 0.020 |
Why?
|
| G1 Phase | 1 | 2009 | 17 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 128 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2009 | 34 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 271 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 181 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2009 | 11 | 0.020 |
Why?
|
| Convalescence | 1 | 2009 | 6 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 209 | 0.020 |
Why?
|
| Pharynx | 1 | 2009 | 15 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 31 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 23 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 553 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 301 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2008 | 13 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 1619 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 157 | 0.020 |
Why?
|
| Piperidines | 1 | 2009 | 48 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 612 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 257 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 246 | 0.020 |
Why?
|
| RNA, Transfer, Lys | 1 | 2008 | 1 | 0.020 |
Why?
|
| Nepal | 1 | 2008 | 8 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2008 | 11 | 0.020 |
Why?
|
| Gene Flow | 1 | 2008 | 13 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2008 | 24 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 66 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2008 | 74 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 166 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 276 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 788 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 289 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 589 | 0.020 |
Why?
|
| Mothers | 1 | 2008 | 126 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 471 | 0.010 |
Why?
|
| Phylogeny | 1 | 2008 | 496 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 557 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 2855 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 3233 | 0.010 |
Why?
|